Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies-Reference-Cited by-同舟云学术

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies

Published:2018 Issue:2 Volume:16 Page:233
ISSN:1598-9100
Container-title:Intestinal Research
language:en
Short-container-title:Intest Res

Author:

Motoya Satoshi¹,Watanabe Mamoru²,Kim Hyo Jong³,Kim Young Ho⁴,Han Dong Soo⁵,Yuasa Hirotoshi⁶,Tabira Junichi⁶,Isogawa Naoki⁶,Arai Shoko⁶,Kawaguchi Isao⁶,Hibi Toshifumi⁷

Affiliation:

1. IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan.

2. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.

3. Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.

4. Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

5. Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea.

6. Inflammation & Immunology, Pfizer Japan Inc, Tokyo, Japan.

7. Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, Japan.

Funder

Pfizer

Publisher

Korean Association for the Study of Intestinal Diseases

Subject

Gastroenterology

Link

https://synapse.koreamed.org/pdf/10.5217/ir.2018.16.2.233

Reference18 articles.

1. Ulcerative colitis

2. Inflammatory bowel disease in the Asia-Pacific area: A comparison with developed countries and regional differences

3. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: A KASID study

4. Prevalence of ulcerative colitis and Crohn’s disease in Japan

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study;Therapeutic Advances in Gastroenterology;2023-01

2. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs;The Korean Journal of Internal Medicine;2022-09-01

3. Safety and efficacy of long‐term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open;Journal of Gastroenterology and Hepatology;2022-07-21

4. Personalized medicine in inflammatory bowel disease: Perspectives on Asia;Journal of Gastroenterology and Hepatology;2022-06-29

5. Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2022-03-26